Case Report

Seronegative hepatitis C-related fibrosing cholestatic hepatitis after renal transplant: a case report and review of the literature

Nathan J. Shores and James Kimberly

Section of Gastroenterology, Department of Internal Medicine, Wake Forest University Health System, Winston-Salem, NC, USA

Keywords: cholestasis; cirrhosis; hepatic fibrosis; hepatitis C; renal transplant

Case

Ms J is a 52-year-old female who underwent deceased donor renal transplant (RT) in May 2006 for membranous glomerulonephritis after 6 years on haemodialysis. She was initially treated post-transplant with alemtuzumab (Campath) secondary to delayed graft function and was subsequently discharged on tacrolimus, mycophenolate and prednisone for chronic immunosuppression. Ms J tested negative for anti-HCV in her first transplant consultation in 2004 and again just 12 days prior to surgery. Her bilirubin (0.5 mg/dL), alkaline phosphatase (ALP 94 IU/L), aspartate aminotransferase (AST 28 IU/L) and alanine aminotransferase (ALT 14 IU/L) were all within normal limits before transplant.

Subsequently, Ms J’s alkaline phosphatase rose to 178 IU/L 7 days after procedure. Within 6 months her aminotransferases (AST 96 IU/L and ALT 78 IU/L) and bilirubin (1.5 mg/dL) became elevated as well, never returning normal. At that time tacrolimus was stopped in favor of anti-HCV in her first transplant consultation in 2004 and again just 12 days prior to surgery. Her bilirubin (0.5 mg/dL), alkaline phosphatase (ALP 94 IU/L), aspartate aminotransferase (AST 28 IU/L) and alanine aminotransferase (ALT 14 IU/L) were all within normal limits before transplant.

During this period, Ms J’s liver chemistries remained stable until 18 months post-RT, when Ms J’s alkaline phosphatase rose to 178 IU/L 7 days after procedure. Within 6 months her aminotransferases (AST 96 IU/L and ALT 78 IU/L) and bilirubin (1.5 mg/dL) became elevated as well, never returning normal. At that time tacrolimus was stopped in favor of cyclosporine, and computed tomography (CT) of the abdomen demonstrated cholelithiasis and small ascites. Despite this, an elective laparoscopic cholecystectomy did not result in improved liver chemistries and several repeat measurements of chronic anti-HCV antibody serologies remained negative. Testing for abnormal antinuclear antibodies (ANA), anti-smooth muscle antibody (ASMA), anti-mitochondrial antibody (AMA) and quantitative immunoglobulins was also negative. Unfortunately, HCV RNA testing was not done. Over the next 7 months, Ms J became increasingly jaundiced with worsening, symp-omatic ascites. This corresponded with declining renal graft function and uraemia.

A gastroenterology consult led to a transjugular liver biopsy 13 months after RT indicated cholestasis, periportal fibrosis and acute inflammation of the bile ducts with associated regeneration, and only mild lobular inflammation (figure 1). Features of HCV hepatitis were absent. A repeated anti-HCV assay at that time was negative, but HCV RNA by B-DNA was positive for $7.69 \times 10^6$ eq/mL of genotype 1a virus. Ms J was diagnosed with FCH C cirrhosis with renal allograft dysfunction from acute tubular necrosis and chronic rejection. She was felt to be unsuitable for HCV therapy and is currently exploring combined liver and RT.

Discussion

Only 14 cases of FCH in RT recipients secondary to HCV infection have been previously described. Prior to Zyldeberg et al.’s original report in 1995, FCH was an ominous complication of immunosuppressed liver transplant recipients infected with HBV and—less often—HCV [1–5]. Several other reports confirmed that a small subset of HCV-infected RT patients develop a rapidly progressive FCH, characterized by acute cholangiolitis, hepatocellular swelling and mild periportal fibrosis rather than the acidophilic hepatocyte necrosis, lobular inflammation or pericellular/sinusoidal fibrosis associated with HCV hepatitis [1, 6–10].

Munoz et al. was the next to report FCH as a rare, but serious, complication in a cohort of known HCV-infected patients (4 out 259) status post-renal transplantation [11]. Like Ms J, these four patients were predominantly genotype 1, lacked the typical features of HCV hepatitis and had a rapid progression to severe liver dysfunction and/or death (Table 1). In Delladetsima et al.’s subsequent report of FCH in four seronegative HCV-infected RT recipients—despite abrupt immunosuppression reduction in all four patients—only two patients seroconverted and had rapid improvement of their liver disease [7]. Similar to Ms J, three of the four patients were genotype 1, and all were on methylprednisone, azothiporine and...
cyclosporine A. Also like Ms J, two persistently anti-HCV negative patients suffered progressively worsening liver function and end-stage liver disease within 18 months of RT. The authors propose this phenomenon may be secondary to peri-operative infection and aggressive post-transplant immunosuppression.

A follow-up retrospective analysis by the same group sought to clarify the effect that the timing of HCV infection had on the development of FCH in 17 RT recipients who were seronegative at the time of transplant, but who developed HCV RNA positive disease after surgery [6]. As in our case, this study observed a short mean time to new biochemical abnormalities in liver function (5.7 months) in the four patients diagnosed with FCH. Also, three patients with FCH at the time of the first biopsy (including the two who never seroconverted) were on triple immunosuppression and infected with HCV genotype 1. Finally, two persistently anti-HCV negative patients fared poorly, dying with advanced liver disease in a median of 6 years.

The factors influencing this rare complication remain unclear. Further study is indicated to determine if the FCH pattern of liver damage in RT patients is related to the timing of infection, aggressive early immunosuppression, patient-specific properties of immunity or HCV genotype as our case and previous reports suggest. Additionally, this case highlights the role of HCV RNA for screening in an immunosuppressed population. While the false negative rate of anti-HCV testing for chronic HCV in high prevalence populations is 5%, multiple studies indicate a failure to form measured antibodies in up to 15% of haemodialysis and transplant patients [12–16]. Unfortunately, it was too long presumed that anti-HCV antibody alone was an adequate diagnostic tool in this case. Like Ms J, RT candidates would benefit from early HCV RNA testing for pre-surgical screening or to diagnose post-RT liver abnormalities. Finally, reversal of clinical liver disease in these patients has been reported with the discontinuation of immunosuppression or the use of PEG interferon, but obviously the experience is limited [17]. A prospective trial is needed to confirm if pre- or post-transplant anti-HCV therapy will positively affect transplant outcomes.

Table 1. Clinical characteristics of patients diagnosed with HCV-related FCH after RT

| Study               | No. of FCH cases | No. of genotype 1 cases | Cirrhosis/liver transplant/deceased | +Anti-HCV pre-RT in FCH cases |
|---------------------|------------------|-------------------------|-------------------------------------|-------------------------------|
| Zylbeberg *et al.* [1] | 1                | 1                       | 1                                   | 1                             |
| Munoz *et al.* [11]   | 4 (of 259)       | 3                       | 4                                   | 4                             |
| Delladetsima *et al.* [7] | 4 (of 73)     | 3                       | 2 (persistently anti-HCV negative)  | 0                             |
| Delladetsima *et al.* [6] | 4 (of 17)     | 3                       | 2                                   | 0                             |
| Hooda *et al.* [9]    | 1                | 1                       | 1                                   | 1                             |

FCH: fibrosing cholestatic hepatitis; RT: renal transplant.
Acknowledgements. Thanks is due to Dr. Emmett B. Keeffe, MD of Stanford University, USA for his assistance reviewing this work before publication.

Conflict of interest statement. None declared.

References

1. Zylberberg H, Carnot F, Mamzer MF et al. Hepatitis C virus-related fibrosing cholestatic hepatitis after renal transplantation. Transplantation 1997; 63: 158–160
2. Davies SE, Portmann BC, O’Grady JG et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991; 13: 150–157
3. Booth JC, Goldin RD, Brown JL et al. Fibrosing cholestatic hepatitis in a renal transplant recipient associated with the hepatitis B virus precore mutant. J Hepatol 1995; 22: 500–503
4. Chen CH, Chen PJ, Chu JS et al. Fibrosing cholestatic hepatitis in a hepatitis B surface antigen carrier after renal transplantation. Gastroenterology 1994; 107: 1514–1518
5. Hung YB, Liang JT, Chu JS et al. Fulminant hepatic failure in a renal transplant recipient with positive hepatitis B surface antigens: a case report of fibrosing cholestatic hepatitis. Hepatogastroenterology 1995; 42: 913–918
6. Delladetsima I, Psychogiou M, Sympsa V et al. The course of hepatitis C virus infection in pretransplantation anti-hepatitis C virus-negative renal transplant recipients: a retrospective follow-up study. Am J Kidney Dis 2006; 47: 309–316
7. Delladetsima JK, Boletis JN, Makris F et al. Fibrosing cholestatic hepatitis in renal transplant recipients with hepatitis C virus infection. Liver Transpl Surg 1999; 5: 294–300
8. Delladetsima JK, Makris F, Psychogiou M et al. Cholestatic syndrome with bile duct damage and loss in renal transplant recipients with HCV infection. Liver 2001; 21: 81–88
9. Hooda AK, Puri P, Narula AS et al. Hepatitis C virus-related fibrosing cholestatic hepatitis in a renal transplant recipient. Indian J Gastroenterol 2006; 25: 308–309
10. Dixon LR, Crawford JM. Early histologic changes in fibrosing cholestatic hepatitis C. Liver Transpl 2007; 13: 219–226
11. Munoz De Bustillo E, Ibarrola C, Collina F et al. Fibrosing cholestatic hepatitis in hepatitis C virus-infected renal transplant recipients. J Am Soc Nephrol 1998; 9: 1109–1113
12. Dalekos GN, Boumba DS, Katopodis K et al. Absence of HCV viraemia in anti-HCV-negative haemodialysis patients. Nephrol Dial Transplant 1998; 13: 1804–1806
13. Lok AS, Chien D, Choo QL et al. Antibody response to core, envelope and nonstructural hepatitis C virus antigens: comparison of immunocompetent and immunosuppressed patients. Hepatology 1993; 18: 497–502
14. Chan TM, Lok AS, Cheng IK et al. Prevalence of hepatitis C virus infection in hemodialysis patients: a longitudinal study comparing the results of RNA and antibody assays. Hepatology 1993; 17: 5–8
15. Hadlich E, Alvares-Da-Silva MR, Dal Molin RK et al. Hepatitis C virus (HCV) viremia in HIV-infected patients without HCV antibodies detectable by third-generation enzyme immunoassay. J Gastroenterol Hepatol 2007; 22: 1506–1509
16. Gretchen DR. Diagnostic tests for hepatitis C. Hepatology 1997; 26(3 Suppl 1): S43–S47
17. Thoth CM, Pascual M, Chung RT et al. Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: response to interferon-alpha therapy. Transplantation 1998; 66: 1254–1258

Received for publication: 30.1.08
Accepted in revised form: 21.2.08